Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie de Quatrebarbes

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
La Revue Du Praticien|September 17, 2005
[Bullous pemphigoid]Julie de Quatrebarbes, Pascal Joly
Dermatology (Basel, Switzerland)|November 16, 2005
Cetuximab-induced acneEmmanuel Molinari, Julie De Quatrebarbes, Thierry André, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 4, 2011
Atypical nodular panniculitisDamien Picard, Julie de Quatrebarbes, Isabelle Gueit, et al.
Journal of the American Academy of Dermatology|May 21, 2011
Papular and annular fixed urticarial eruption: a characteristic skin manifestation in patients with relapsing polychondritisAnne-Fleur Tronquoy, Julie de Quatrebarbes, Damien Picard, et al.
Archives of Dermatology|September 21, 2005
Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective studyJulie de Quatrebarbes, Eric Estève, Martine Bagot, et al.
Oncotarget|February 18, 2020
Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre studyHenri Montaudié, Julien Viotti, Patrick Combemale, et al.
JCO Precision Oncology|November 10, 2022
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National CohortManon Girod, Stéphane Dalle, Laurent Mortier, et al.
Melanoma Research|November 11, 2024
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohortCamille Macaire, Wendy Lefevre, Sophie Dalac, et al.
Cancers|September 9, 2023
Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma PatientsConstance Reichert, Capucine Baldini, Sarah Mezghani, et al.
Journal of the American Academy of Dermatology|June 21, 2021
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Stéphane Dalle, Marie-Thérèse Leccia, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
La Revue Du Praticien|September 17, 2005
[Bullous pemphigoid]Julie de Quatrebarbes, Pascal Joly
Dermatology (Basel, Switzerland)|November 16, 2005
Cetuximab-induced acneEmmanuel Molinari, Julie De Quatrebarbes, Thierry André, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 4, 2011
Atypical nodular panniculitisDamien Picard, Julie de Quatrebarbes, Isabelle Gueit, et al.
Journal of the American Academy of Dermatology|May 21, 2011
Papular and annular fixed urticarial eruption: a characteristic skin manifestation in patients with relapsing polychondritisAnne-Fleur Tronquoy, Julie de Quatrebarbes, Damien Picard, et al.
Archives of Dermatology|September 21, 2005
Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective studyJulie de Quatrebarbes, Eric Estève, Martine Bagot, et al.
Oncotarget|February 18, 2020
Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre studyHenri Montaudié, Julien Viotti, Patrick Combemale, et al.
JCO Precision Oncology|November 10, 2022
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National CohortManon Girod, Stéphane Dalle, Laurent Mortier, et al.
Melanoma Research|November 11, 2024
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohortCamille Macaire, Wendy Lefevre, Sophie Dalac, et al.
Cancers|September 9, 2023
Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma PatientsConstance Reichert, Capucine Baldini, Sarah Mezghani, et al.
Journal of the American Academy of Dermatology|June 21, 2021
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Stéphane Dalle, Marie-Thérèse Leccia, et al.
Pageof 3